QuantumCell

QuantumCell is an AI-native, quantum-enabled biotechnology company focused on developing next-generation therapeutics for neuropsychiatry and central nervous system (CNS) disorders. Headquartered in Copenhagen, the company utilizes a proprietary platform that combines quantum technology, high-fidelity virtual cell models, and autonomous robotics to decode complex brain biology. In 2026, QuantumCell secured global rights to the NeuroRestore platform from AlzeCure Pharma, including the lead candidate ACD856, a first-in-class small molecule positive allosteric modulator of Trk receptors. The company is backed by prominent life science investors including Novo Holdings, Lundbeckfonden, and Forbion. Its lead program is currently transitioning into Phase 2 clinical trials for the treatment of Alzheimer's disease. QuantumCell aims to leverage its computational infrastructure to address high unmet medical needs in depression, Parkinson's disease, and other CNS indications.